Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Can Development of a Rash on Erbitux Predict Who Will Benefit?
Author
Howard (Jack) West, MD

The improvement in median survival of 1.2 months with the monoclonal antibody to EGFR erbitux (cetuximab) in the FLEX trial that I've previously described was statistically significant, but there's plenty of room to debate whether it's really clinically significant (see prior post). What If we could add some way to refine our predictions of who will benefit from the addition of erbitux?

At the Chicago Lung Cancer meeting in November 2008, Dr. Ulrich Gatzemeier presented results of a planned subset analysis of the FLEX trial, in which the results compared the outcomes of patients randomized to receive cetuximab by whether they developed an acne-like rash within three weeks of starting this treatment. This was based on a growing and rather consistent experience that patients who receive EGFR inhibitors, whether oral tyrosine kinase inhibitors or IV antibodies, generally show a a strong trend or significantly better survival than patients who develop no rash (see prior post). The investigators found that there was a very significant difference in efficacy with cetuximab among the patients who developed a rash (of any severity) after two weeks (56%) compared with those who didn’t (44%). The difference in median survival was a near doubling: 15.0 months for the patients with any rash, compared with 8.8 months for those who didn’t:

FLEX OS by Rash

First, when you compare the median overall survival of 15 months for the patients who developed an early rash on erbitux to the median survival of 10 months for patients who received chemo alone, this suggests to me that some patients are getting a pretty meaningful benefit from erbitux, but it may be only about half of the people who receive it. If these results are real, and I believe they are, the question is whether we can use the early development of a rash to distinguish between the real beneficiaries of this treatment and those for whom it will just add side effects and cost. The other possibility is that patients who don't develop a rash with erbitux would do worse with any treatment that they happen to receive -- that the association of rash with better survival is prognostic of better outcomes, but not necessarily predictive of doing better specifically with erbitux.

I haven’t been in the practice of pulling people off of a treatment after just a few weeks on the basis of a lack of symptoms, and I think that many patients may be inclined to still continue erbitux, whether they develop a rash or not. But I think that at least we might be able to feel more comfortable that patients who receive erbitux with chemo and develop a rash are likely to get a survival benefit that we’d consider to be genuinely clinically significant.

Next Previous link

Previous PostNext Post

Related Content

Image
Trial data ASCO 2024
Video
In this video series from ASCO 2024, Drs. Aakash Desai and Fauwzi Abu Rous discuss trial dates and clinical data as presented at the 2024 ASCO. To watch the complete playlist, click here.         
Image
Bladder Cancer Video Library 2024
Video
Dr. Petros Grivas discusses intravesical treatment for patients with nonmuscle invasive, or early-stage, bladder cancer, the importance of participating in clinical trials for bladder cancer, combination therapy options for patients with metastatic or incurable bladder cancer, and the importance of family history of cancer and discussing that history with your doctor.
Image
Case Based Panel
Video
The panel discusses treatment options for a patient diagnosed with EGFR Exon 19 Deletion NSCLC and examines data from the Laura Trial, a patient with a smoking history and diagnosis of small cell lung cancer, and how the Adriatic Study factors into decisions, and a patient with NSCLC adenocarcinoma, and a EGFR Exon 21 L858R Alteration, and how data from the Flaura 2 Trial can impact treatment decisions.

Forum Discussions

Hi elysianfields and welcome to Grace.  I'm sorry to hear about your father's progression. 

 

Unfortunately, lepto remains a difficult area to treat.  Recently FDA approved the combo Lazertinib and Amivantamab...

Hello Janine, thank you for your reply.

Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...

Hi elysianfields,

 

That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...

Recent Comments

JOIN THE CONVERSATION
I could not find any info on…
By JanineT GRACE … on
Hi elysianfields,

 

That's…
By JanineT GRACE … on
Hello Janine, thank you for…
By elysianfields on
EGFR
By happybluesun on